Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
those are my thoughts exactly...
88 shares so far..something must be up!
honestly though. I have a few mill shares that I :
cannot move from merril lynch, get a stock certificate or sell. LOL ..
guess I am stuck here with you guys for awhile
why do you keep referring to this Ronnie guy and things crap from 5 years ago?
man you are pretty quick..
NOT actual stock dividends
but future positivive dividends
like: a benefit from an action or policy.
"persistence pays dividends"
VDRM has a great looking chart.. next time it goes it will really go..
Sounds like you low IQ folks are panicking...
what ? that is crazy talk..
anyway volume is great and "something" is going on...
14's are up now... Volume approaching 90 mill already
big continuation of buying volume so far.. 12's on deck..
quantifiable? personal relationships are everything.
True... But it seems like they are getting ready in a very structured manner currently rather than haphazardly slinging PR's at the wall like previous MGT(s).. Of course the major first step needed is the Stop sign removal via completed financials. but they are coming
agree- volume is blowing up. might be a custodian play or clean shell take over. Not many clean shells left....
volume approaching 200 Million on nothing.. lot of trades too.
Looks good to me. Other income streams. The bottling plant is paying big dividends which will be shown when the financials and future 8k's are approved and released
Seems like this. is a shell play. and Volume is spiking up lately.
when we are over 100m shares per day for no reason then something is up....
NEWS Rocky Mountain High Brands Makes Strategic Investment in Private Branded and NBE Consumer Products Sector
PLANO, Texas, Jun 16, 2021 (GLOBE NEWSWIRE via COMTEX) -- PLANO, Texas, June 16, 2021 (GLOBE NEWSWIRE) -- Rocky Mountain High Brands, Inc. (OTCPK: RMHB), today announced that it has entered into a trademark license agreement with AGS Labs, Inc. to produce certain AGS Great Choice products. Great Choice (R) is a trademarked name owned by AGS.
The products include the Great Choice Pediatric Electrolyte Solution, Great Choice Medicated Chest Rub, and Great Choice Infant Rub. These products are National Brand Equivalent (NBE) products and compare with national brands, such as Pedialyte beverages. The NBE market is a rapidly growing market, and the Company is exploring adding additional NBE product and business lines. The Agreement also grants to the Company a binding option to purchase the above mentioned Great Choice national brand equivalents and the "Great Choice" trademark.
Great Choice(R) is a control brand that augments AGS Labs' customer base, which creates trust and credibility, leading to brand loyalty - all of which gave the Company a competitive edge in the market and a bigger bottom line. For consumers, Great Choice products offer the highest quality product and significant savings to advertised brands. Brands are one of the most important and valuable assets that a company owns. Successful branding can help the company attract and retain a customer base, which can lead to brand loyalty while giving it an advantage on the competition.
The Agreement continues the Company's emphasis on growing the production capacity of its wholly owned subsidiary, Rocky Mountain Production, Inc., by strategically investing in select assets with the highest potential future value to increase earnings potential while maintaining flexibility to further adjust priorities as the market evolves.
About AGS Labs, Inc.
AGS Labs develops and distributes Over The Counter (OTC) National Brand Equivalent (NBE) products focused on cough and cold, electrolytes, gastrointestinal, vitamins, analgesics in both liquid and powder form under their Great Choice trademark. The company was founded in 1988 as a provider of liquids, lotions, powders, and gels.
About Rocky Mountain High Brands
Rocky Mountain High Brands, Inc. is a diversified and dynamic young Company committed to making a difference by raising the quality and expectations in beverages and personal protection sanitizer products. We are committed to producing healthier beverages with innovative flavors designed to help people feel inspired as well as creating sanitizer products for a safer lifestyle.
Our Eagle Spirit(R) is a high alkaline spring water that has a high pH, an all-natural refreshing taste, and is sourced from sacred Native American soil rich in history and culture. The name of Eagle Spirit represents great power and balance, dignity with grace, and a symbolism as to live in balance with heaven and earth.
Our enriched flavor-infused waters with CBD sold under the brand of Hempd(TM) are market disrupters. These innovated drinks were formulated by our own talented team who are transcending the beverage frontier with their creativity and passion for healthier alternatives to the sugar-ridden drinks that dominate the market today. Hempd(TM) currently offers four unique flavors including Peach Mango, Pineapple Coconut, Dragon Fruit, and Raspberry Lemonade with zero calories. New flavors are coming soon including our original legacy drinks made with hempseed oil.
Our CEO, President, and CFO will be providing an overview of our business and drug development pipeline during the Ladenburg Thalmann Healthcare Conference.
Watch our presentation virtually on July 13th at 3:00PM EDT.
$TRYP $TRYPF
https://meetmax.com/sched/event_72617/conference_home.html?bank_access=0&event_id=72617
TRYP CEO Greg McKee joined Steve Darling from Proactive to talk about his new role as Chairman and CEO. McKee talks about his background and what he sees moving forward for the company. We discuss the company's pipeline and how close we are to starting our clinical trials with University of Florida and some of the other work we're doing on our Psilocybin-for-Neuropsychiatric Disorders program targeting chronic pain. We also give an update on razoxane with his designed for soft tissue sarcomas.
Our recent partnership with
@AlcamiNow
will help us develop safe and controlled oral delivery methods for our proprietary psilocybin.
We expect to manufacture our initial batch of cGMP psilocybin API in September.
Our recent partnership with @AlcamiNow will help us develop safe and controlled oral delivery methods for our proprietary psilocybin.
— Tryp Therapeutics (@TrypTherapeutic) June 7, 2021
We expect to manufacture our initial batch of cGMP psilocybin API in September.$TRYP $TRYPF
VDRM with a Brilliant daily chart...
will test ATH at 7.5 ish then blow through that ...
Tryp Therapeutics Featured in USA Today
Top 10 Entrepreneurs to Watch as they Innovate and Expand Companies in 2021
What do companies like Microsoft, Apple, Netflix and Airbnb all have in common? Aside from billion-dollar valuations, these industry titans were all founded amid recessions, scaling to the pinnacle of success in the aftermath.
Spanning from 1975 with the conception of Microsoft during a 16-month recession that saw the gross domestic product value take its worst hit in nearly two decades to 2008 when Airbnb arose from the ashes of the subprime mortgage crisis, these examples prove that adversity does indeed breed innovation.
With the COVID-19 pandemic of 2020 catalyzing yet another recession, in which more than 50 million Americans filed for unemployment insurance within mere months of its onset, it is no question that this is a time where great innovation is unfolding.
The 10 entrepreneurs listed below are at the forefront of driving this innovation and bringing about societal change. As they pivot and expand their business models to embrace the world we now live in, countless eyes are passionately watching to see how far they will leap as they overcome this period of adversity.
Here are the 10 Companies to Watch in 2021
https://amp.usatoday.com/amp/5148534001
As we enter our next phase of growth, we are building important new partnerships with companies like
@AlcamiNow
,
@Clinlogix
and
@Fluencetraining
to help validate psychedelics and develop the next generation of medicine.
$TRYP $TRYPF
As we enter our next phase of growth, we are building important new partnerships with companies like @AlcamiNow, @Clinlogix and @Fluencetraining to help validate psychedelics and develop the next generation of medicine.$TRYP $TRYPF
— Tryp Therapeutics (@TrypTherapeutic) June 1, 2021
Chart is beautiful.
It is as easy as this:
A close over .04 equals at least a retest of the ATH -.0765
I like your thinking....
Stop Obsessing about the "other board"
no one cares.
get outside and enjoy life...
Beef is comin'
Lighten up! You guys sure can dish it out day after day.. But you really can't take it.
Here is your chance- don't be silly to sell for a cheesy 50-100% ...
Have a great weekend
hey..
I never called you or anyone any name..
But that is ok. Just trying to have some Friday Fun.
Don't take everything so personally ;)
is that you who has 1 million share son the Bid? ;)
NEWS-Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Brings Best-in-Class Team to Psychedelics Development
Tryp Therapeutics Inc.
Fri, May 21, 2021, 5:30 AM
TRYPF
+0.68%
NEW YORK, May 21, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Wall Street Unicorns in Process of Changing the Healthcare Landscape.”
To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast
To view the full editorial, please visit: https://nnw.fm/QOAcO
Most people may not recognize some of the medical terms for psychedelics, but nearly all know their street names, including magic mushrooms, ecstasy, Molly and LSD. Over decades, people have been conditioned to the stigma of these illicit substances, instigated and promoted by the Controlled Substances Act. However, the negative stigma is being lifted and being replaced by a growing body of scientific clinical evidence that strongly suggests psychedelics may well become one of the greatest advancements in mental health and neuropsychiatric disease in decades. . . .
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) offers a best-in-class, drug development team capable of taking compounds from early stage and advancing them through the rigors of clinical development to commercialization. This team of executives and advisors cannot go understated as it’s made up of deep experience and key leadership positions throughout, including large pharma, emerging pharma, drug approvals, psychedelics and capital markets.
About Tryp Therapeutics Inc.
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and safety profiles for the treatment of rare and other diseases with unmet medical needs. Tryp’s psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of certain neuropsychiatric-based disorders. Tryp’s lead PFN drug candidate is TRP-8802 for the treatment of fibromyalgia, a chronic pain syndrome estimated to affect more than five million people in the United States. The company is also preparing to initiate a phase 2a clinical study for eating disorders in partnership with the Dr. Jennifer Miller at the University of Florida. In addition to its PFN program, Tryp is developing TRP-1001, an oral formulation of razoxane for the treatment of soft-tissue sarcoma. Soft-tissue sarcomas are a rare and diverse group of tumors that account for about 1% of all cancers in adults and 7% in children. Based on the prevalence of soft-tissue sarcomas in the United States, Tryp believes it is a rare disease and that TRP-1001 should qualify for orphan drug status.
For more information about the company, please visit www.TrypTherapeutics.com.
because maybe your post that -you posted over there is FAKENEWS b.s.?
Just a thought..
better hop on the RMHB train cowboy..
so you can make your $18.46 when you flip this again.
George Coates has been responsive to emails again-after years of not . They are still working hard down at the Wall TWp facility and have very very lofty goals. IMO- Not sure if revoked can get un-revoked... still but it's good to see he is super inspired.
A slight heartbeat ....
coinbase Pro is a POS...
Was trying to log in to buy ETH this AM on the spike down and needless to say-- they suck...
I already had orders in place for months- between 1k-1.8k and was trying to login to redo those buys and buy some ATM but - site was down.
it's not a good look..
Mega Bid building up here....
Stop fighting it.. sounds like you guys are gettting desperate.
No one is selling. Diamond Hands..
and there you go.
Heading the right course..
when that health network deal is announced we should surpass previous highs
Fake like you...
TYRPF- OTCQB
We are pleased to announce our listing on the OTCQB market and DTC eligibility, marking our entry into the US financial markets under the symbol "TRYPF". This new listing will allow us to attract new investors passionate about psychedelics
TRYP- We have submitted a provisional patent to improve the formulation, delivery, and dosing of psychedelics, potentially reducing time patients spend in a dissociative state, further supporting a more controlled psychedelic experience.
$TRYP $TRYPF
twitter: @TrypTherapeutic
We're very excited to have the experience of Greg McKee leading Tryp Therapeutics.
His background leading publicly traded pharmaceutical companies, as well as his experience in biotech and drug development, will be incredibly valuable in our next phase of growth.
There are currently no approved drugs and only limited treatment options for patients with rare over-eating disorders.
That's why we are focusing on developing our TRP-8802 novel formulation to better address these rare and debilitating disorders.
$TRYP $TRYPF